Anders Fink-Jensen

Anders Fink-Jensen

Clinical Professor

Member of:

  • Psychiatry


Publication year:
All
1 - 7 out of 7Page size: 10
  1. 2019
  2. Published

    Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys

    Thomsen, M., Holst, Jens Juul, Molander, A., Linnet, Kristian, Ptito, M. & Fink-Jensen, Anders, Feb 2019, In: Psychopharmacology. 236, 2, p. 603–611

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial

    mfw347, mfw347, Correll, C. U., Rudå, D., Klauber, D. G., Decara, M. S., Fagerlund, Birgitte, Jepsen, J. R. M., Eriksson, Frank, Fink-Jensen, Anders & Pagsberg, Anne Katrine, 2019, In: Journal of the American Academy of Child and Adolescent Psychiatry. 58, 11, p. 1062-1078 17 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs

    Bornebusch, A. B., Fink-Jensen, Anders, Wörtwein, G., Seeley, R. J. & Thomsen, M., 2019, In: eNeuro. 6, 2, 17 p., e0443-18.2019.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis

    Siskind, D., Hahn, M., Correll, C. U., Fink-Jensen, Anders, Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishoy, P. L., Vilsbøll, Tina, Knop, Filip Krag, Kisely, S. & Ebdrup, Bjørn, 2019, In: Diabetes, Obesity and Metabolism. 21, 2, p. 293-302 10 p.

    Research output: Contribution to journal › Review › Research › peer-review

  6. Published

    High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine

    Larsen, J. R., Svensson, C. K., Vedtofte, L., Jakobsen, M. L., Jespersen, H. S., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, Claus Thorn, Holst, Jens Juul, Correll, C. U., Vilsbøll, Tina & Fink-Jensen, Anders, 2019, In: CNS Spectrums. 24, 4, p. 441-452 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients

    Svensson, C. K., Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, Claus Thorn, Correll, C. U., Vilsbøll, Tina & Fink-Jensen, Anders, 2019, In: Acta Psychiatrica Scandinavica. 139, 1, p. 26-36 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review

    Brunchmann, A., Thomsen, M. & Fink-Jensen, Anders, 2019, In: Physiology and Behavior. 206, p. 232-242 11 p.

    Research output: Contribution to journal › Review › Research › peer-review

ID: 916366